In recent years, considerable progress has been made in the molecular mechanisms of epigenetics in disease development and progression, the reversible characteristics of epigenetic modification provide new insights for the treatment of such diseases. The pathogenesis of diabetic retinopathy (DR) has not yet been fully understood, treatment of refractory and recurrent diabetic macular edema remains a big change in clinical practice. This review emphasizes that reversibility of epigenetic modification could provide a new strategy for the prevention and treatment of diseases.
基金：
“The National Natural Science
Foundation of China (Grant No: 81170859 and 81570850)”, “Beijing
health system high-level talent project (Grant No: 2013-3-056)” the Grant
2016YFC1305600, 2016YFC1305601 from the Major Chronic Non-communicable
Disease Prevention and Control Research Key Project of the Ministry of
Science and Technology of the People’s Republic of China
第一作者机构：[1]Capital Med Univ,Tongren Hosp,Beijing Ophthalmol & Visual Sci Key Lab,Beijing Inst Ophthalmol,Beijing Tongren Eye Ctr,Beijing 100730,Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Xinyuan,Zhao Lin,Hambly Brett,et al.Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets[J].CELL AND BIOSCIENCE.2017,7:doi:10.1186/s13578-017-0167-1.
APA：
Zhang, Xinyuan,Zhao, Lin,Hambly, Brett,Bao, Shisan&Wang, Kaiyue.(2017).Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets.CELL AND BIOSCIENCE,7,
MLA：
Zhang, Xinyuan,et al."Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets".CELL AND BIOSCIENCE 7.(2017)
